Investing in ways to utilize the vast army of microbes existing in their bodies which humans depend on to stay alive is the focus of Seventure Partners' Health for Life Capital vehicle, the world’s first investment fund aimed at health and nutrition. The VC's partner responsible for investments in the Benelux, Scandinavia, Northern Switzerland and North America outlines in a television interview the strategic thinking behind the fund and investment opportunities in life sciences, including biotechnology and pharmaceuticals and connected health and medtech, industrial biotechnology, and the microbiome comprising nutrition, food-tech and personalized medicine.
Seventure Partners Fund Focuses On Microbiome Revolution
Listen to this article
Seventure Partners' new VC fund focused on the microbiome revolution has €160m to invest in the areas of health and nutrition.
Keep up with the top pharma business news of the week. On the go.
More from Archive
Optimizing Drug Pipelines With Biophysical Methods”, your view into how using biophysical techniques can enhance and streamline processes throughout the drug discovery and validation cycle.
• By
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
• By
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
• By
GSK will assume full control of mRNA shots in infectious disease, allowing CureVac to cut costs and pivot its research to oncology.
More from Scrip
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains